HTB

Antiretrovirals

Viral dynamics of dolutegravir-based dual versus triple ART

Ibalizumab: 48-week phase 3 results in 27 participants with MDR HIV

Fostemsavir: 48-week phase 3 results from BRIGHTE study

Dolutegravir non-inferior to low dose efavirenz in real-life African study conducted in Cameroon  

Dual bNAb maintains viral suppression for median 21 weeks off-ART

Cabotegravir levels can be detected several years: PK tail to be covered by oral PrEP

FDA updates rilpivirine label for use during pregnancy

Dolutegravir/lamividune FDC submitted to EMA and FDA

English court finds in favour of access to generic TDF/FTC

FDA approves doravirine (Pifeltro) and new FDC with TDF/3TC (Delstrigo) in the US

FDA update labels for dolutegravir and dolutegravir-based FDCs to reflect potential risk of neural tube defects

Top-line phase 3 results released for cabotegravir/rilpivirine long-acting injections

Interactions between oral anticoagulants and Genvoya, Stribild and cobicistat: FDA label updates

DTG/3TC dual therapy is non-inferior to triple-ART in GEMINI study

Superior efficacy with dolutegravir-based ART compared with other regimens at 6 months: real-world data from Brazil 

Featured Fit for purpose: Antiretroviral treatment optimisation

Featured HIV pipeline 2018: full version

Bictegravir/FTC/TAF (Biktarvy) approved in Europe

New contraindication against using darunavir/cobicistat during pregnancy

China approves albuvirtide: a once-weekly injectable entry inhibitor

Single dose PRO140 mAb reduces viral load by 0.5 log copies/mL in people with multidrug resistance

EMA approves dolutegravir/rilpivirine (Juluca) in Europe as dual-therapy HIV switch option

Meta-analysis of TAF vs TDF in boosted vs unboosted regimens

Meta-analysis of dolutegravir in naive, experienced and switch studies

Drug cost savings from routine use of generic ARVs: safety and efficacy in practice

Ibalizumab 24-week phase 3 results and susceptibility to drug-resistant HIV

Bictegravir at CROI 2018: switching studies and drug resistance analyses

FDA approves ibalizumab in the US to treat multidrug HIV resistance

FDA grants tentative approval to first DTG/FTC/TAF FDC

Bictegravir approved in the US in new integrase-inhibitor based FDC (Biktarvy)

US approve a lower-dose efavirenz (400 mg) based generic FDC (Simfi Lo)

ViiV announces phase 3 study switching to dolutegravir/3TC dual therapy from TAF-containing ART

US darunavir label updated: drug interactions and pregnancy

Doravirine FDC submitted to FDA in US: decision expected October 2018

FDA approves raltegravir for newborns

Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results

D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets

Switch study shows F/TAF non-inferior to continuing abacavir/3TC

No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed

ABX464 nudges viral reservoir but not time to viral rebound

Long-acting ART for children is a deferred priority despite achievable dosing

Coformulated dolutegravir plus rilpivirine approved in US (Juluca)

Darunavir-based single pill FDC approved in EU (Symtuza)

Dual therapy with darunavir/r plus lamivudine as first-line ART

Dual therapy with dolutegravir plus lamivudine as first-line ART

Once-daily raltegravir: 96-week results from the ONCEMRK study

Gilead uses voucher to speed FDA review of bictegravir

HIV pipeline drugs: IAS 2017 update

Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study

Phase 3 results with bictegravir FDC: a new integrase inhibitor combined with FTC/TAF

Doravirine/3TC/TDF compared to efavirenz/FTC/TDF as first-line ART

Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results

Reduced-dose darunavir is safe and effective in switch study

MK-8591: further compelling early results for both treatment and prevention

Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

First dolutegravir-based FDC gets FDA tentative approval

FDA grant priority review for ibalizumab

Introduction to HIV pipeline 2017

HIV pipeline 2017: full version

HIV pipeline 2017: summary version

HIV pipeline 2017: Update from IAS Paris

Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs

Dolutegravir pharmacokinetics in pregnancy

High rates of of undocumented efavirenz-related side effects in Uganda

Increased risk of ART failure after low-level viraemia in a large South African cohort

Post navigation